Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00406237 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Study Of Tigecycline In Adult Subjects With Primary Biliary Cirrhosis
A Phase 1 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT00406237 is a Phase 1 study that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 8 participants.
The verdict
NCT00406237, a Phase 1 study, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
Open label, single dose study of the pharmacokinetics of tigecycline in adult subjects with primary biliary cirrhosis (PBC)
Interventions
- DRUG tigecycline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2006-12 |
| Est. Completion | 2009-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00406237
The ClinicalTrials.gov registry entry for NCT00406237 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which tigecycline is the first listed.
NCT00406237 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00406237 about?
NCT00406237 is a clinical study titled "Pharmacokinetic Study Of Tigecycline In Adult Subjects With Primary Biliary Cirrhosis". Open label, single dose study of the pharmacokinetics of tigecycline in adult subjects with primary biliary cirrhosis (PBC)
What is the current status of trial NCT00406237?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2006-12. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00406237?
The interventions under investigation include: tigecycline (DRUG).
Who is sponsoring clinical trial NCT00406237?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.